Outcomes after transcatheter aortic valve replacement in older patients

Transfemoral transcatheter aortic valve replacement (TF-TAVR) has evolved to the standard of care for patients with severe symptomatic aortic valve stenosis who are at prohibitive, high, and even intermediate risk for surgical aortic valve replacement [1–4]. The prevalence of aortic valve stenosis is increasing due to the continuously growing geriatric population [4–6]. However, data on procedural success and mortality of very old patients are sparse, raising the question of when is this population “too old even for TAVR.” In addition, the incidence of some TAVR-associated complications (stroke, vascular complications) appears to be more frequent in elderly patients [6]. Nevertheless, current data show that avoidance of preparatory balloon aortic valvuloplasty (BAV) can be associated with procedural simplification and thus lower complication rates [7]. The purpose of the present study was therefore to evaluate the influence of age on outcome after TF-TAVR and the possible impact of direct implantation in very old patients.

Patients and methods

Patient population

Data from 394 consecutive high-risk patients with symptomatic aortic valve stenosis who underwent transfemoral (TF) TAVR in our center using the Medtronic Corevalve Evolut R (MER) or Medtronic Evolut Pro (MEP; Medtronic Inc., Minneapolis, MN, USA; n = 44), the Edwards SAPIEN 3 (ES3; Edwards Lifesciences Inc., Irvine, CA, USA; n = 258), the Symetis ACURATE neo (SAN; Boston Scientific Corporation, Natick, MA, USA; n = 71), the Direct flow (DF; Direct Flow Medical, Santa Rosa California, USA; n = 19), and the Portico (Abbot Vascular, Illinois, USA; n = 2) bioprostheses were analyzed retrospectively. Patients were divided into four age groups: age ≤75 (group 1, n = 28), 76–80 (group 2, n = 107), 81–85 (group 3, n = 148), and >85 years (group 4, n = 111). Due to the increased frailty, direct implantation without preparatory BAV was more frequently performed on patients aged over 85 years (group 4) due to procedure simplification. The decision for TAVR was made by an interdisciplinary heart team [1, 8, 9]. All TAVR procedures were performed according to standard techniques and guidelines [8–11].

Paravalvular leakage

Residual paravalvular leakage (PVL) was graded qualitatively according to the Sellers criteria [12]. In order to assist on-table decision-making, the amount of regurgitating contrast medium during supra-aortic angiography after final device deployment defined PVL severity [12, 13]: absent 0/4, mild 1/4, moderate 2/4, moderate-to-severe 3/4, and severe 4/4 [12, 13]. In addition, simultaneous left ventricular (LV) and aortic pressures were recorded at 50 mm/s and averaged over three representative

| Abbreviations          | Description                                      |
|------------------------|--------------------------------------------------|
| BAV                    | Balloon aortic valvuloplasty                     |
| DAP                    | Diastolic aortic pressure                        |
| ΔP_DAP-LVEDP           | Pressure gradient between DAP and LVEDP          |
| LVEDP                  | Left ventricular end-diastolic pressure          |
| PVL                    | Paravalvular leakage                             |
| THV                    | Transcatheter heart valve                        |
cardiac cycles after the procedure [12, 13]. For quantitative evaluation of PVL severity, the pressure gradient between diastolic aortic and left ventricular end-diastolic pressure ($\Delta P_{\text{DAP-LVEDP}}$) was assessed [12]. A $\Delta P_{\text{DAP-LVEDP}} \leq 18$ mmHg has been previously associated with increased mortality, especially in cases of relevant PVL after TAVR [12].

**Endpoint**

The primary endpoint was all-cause mortality at 30 days and 1 year according to the Valve Academic Research Consortium (VARC II) definitions [10]. The incidence of other TAVR-associated complications, with a focus on stroke and vascular complications, and THV performance were further evaluated. The follow up period was 1 year.

**Postinterventional protocol**

After TAVR, patients were transferred for 24 h to an intensive care unit for postinterventional monitoring. Besides the clinical examination, electrocardiogram, body temperature check, and chest x-ray, all blood parameters that had already been determined at the initial examination were assessed again. Follow-up examinations were performed 30 days and 1 year after discharge.

**Statistical analysis**

Categorical data are presented as frequencies and percentages; continuous variables are presented as means and standard deviation. The normal distribution of the variables was tested by the Shapiro–Wilk test ($p \geq 0.1$). Comparisons were made with two-sided $\chi^2$ tests or two-sided Fisher’s exact tests for categorical variables and one-way ANOVA for continuous variables, using Bonferroni correction for multiple testing. An ANOVA and $t$ test were used to compare normally distributed variables and the Mann–Whitney test to compare the other non-normally distributed variables between the four age groups. Statistical significance was set at $p < 0.05$. Survival analyses for the four age groups were performed using the Kaplan–Meier method, with patients censored as of the last date known alive. All statistical analyses were performed using SPSS (version 17.0, SPSS, Chicago, IL, USA). The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.

**Results**

**Baseline and procedural characteristics**

Our study cohort represents a typical TF-TAVR patient population deemed as
had significantly less weight and height as expected, significantly older and In addition, patients in group 4 were, vs. 20.9±12.2, respectively, p
(12.7±10.0 vs. 11.5±7.5 vs. 14.8.±9.9
had a significantly higher EuroSCORE
47.0±16.0mmHg). Patients in group 4
area 0.7±0.2cm², transvalvular gradient
symptomaticaorticstenosis(aorticvalve
other age groups.

Abstract

Background. The prevalence of aortic valve stenosis is increasing due to the continuously growing geriatric population. Data on procedural success and mortality of very old patients are sparse, raising the question of when this population may be deemed as "too old even for transcatheter aortic valve replacement (TAVR)." We, therefore, sought to evaluate the influence of age on outcome after TAVR and the impact of direct implantation.

Methods. The data of 394 consecutive patients undergoing TF-TAVR were analyzed. Patients were divided into four age groups: ≤75 (group 1, n = 28), 76–80 (group 2, n = 107), 81–85 (group 3, n = 148), and >85 (group 4, n = 111) years. Direct implantation was performed when possible according to current recommendations. Survival was evaluated by Kaplan–Meier analysis.

Results. Mortality at 30 days and 1 year was not significantly different between the four age groups (3.6 vs. 6.7 vs. 5.4 vs. 2.7% and 7.6 vs. 17 vs. 14.5 vs. 13% respectively, log-rank p = 0.59). Direct implantation without balloon aortic valvuloplasty was more frequently performed on patients aged >85 vs. ≤85 years (33.3 vs. 14.1%, p < 0.001). The incidence of procedural complications frequently associated with advanced age (stroke, vascular complications) was not significantly increased in group 4.

Conclusion. Outcome after TF-TAVR is comparable among different age cohorts, even in very old patients. Direct implantation simplifies the procedure and could therefore play a role in reducing the incidence of peri-interventional complications in patients of advanced age.

Keywords
Aortic stenosis - Balloon valvuloplasty - Direct implantation - Aged - Outcome

Table 1a

| Group | Age Range | Number | Procedural Success | Mortality at 30 Days | Mortality at 1 Year |
|-------|-----------|--------|--------------------|----------------------|--------------------|
| 1 | ≤75 | 28 | 96.4% | 3.6% | 14.1% |
| 2 | 76–80 | 107 | 98.1% | 6.7% | 17% |
| 3 | 81–85 | 148 | 97.9% | 5.4% | 14.5% |
| 4 | >85 | 111 | 94.6% | 2.7% | 13% |

Table 1b

| Group | Age Range | Number | Procedural Success | Mortality at 30 Days | Mortality at 1 Year |
|-------|-----------|--------|--------------------|----------------------|--------------------|
| 1 | ≤75 | 28 | 96.4% | 3.6% | 14.1% |
| 2 | 76–80 | 107 | 98.1% | 6.7% | 17% |
| 3 | 81–85 | 148 | 97.9% | 5.4% | 14.5% |
| 4 | >85 | 111 | 94.6% | 2.7% | 13% |

Fig. 1

There were no other significant differences in baseline and postprocedural characteristics between the four age groups (Table 1a, b).

Mortality and peri-interventional complications

Mortality at 30 days and 1 year was not significantly different between the four age groups (3.6 vs. 6.7 vs. 5.4 vs. 2.7% and 7.6 vs. 17 vs. 14.5 vs. 13%, respectively, log-rank p = 0.59; Fig. 1). Direct implantation without balloon aortic valvuloplasty was more frequently performed on patients aged >85 vs. ≤85 years (33.3 vs. 14.1%, p < 0.001). The incidence of procedural complications frequently associated with advanced age (stroke, vascular complications) was not significantly increased in group 4 (Table 1b). In a further analysis, patients aged ≤85 and >85 years were compared. Patients aged >85 showed a statistically nonsignificant trend toward a better outcome than patients aged ≤85 (log-rank= 0.578, Fig. 2).
Paravalvular leakage after TAVR

The angiographic assessment of postprocedural PVL revealed a similar distribution of PVL severity after TF-TAVR (Table 2a) between patients aged ≤85 and >85 years. Severe PVL did not occur in any of our study patients. Hemodynamic assessment of PVL severity showed a similar incidence in the pressure difference of ΔP_{DAP-LVEDP} <18 mm Hg between the two groups (Table 2b).

Impact of THV type on direct implantation and mortality

Direct implantation was performed significantly more frequently with the ES3 bioprosthesis (n = 54 patients, 70.1%) than the MER or MEP bioprosthesis (n = 23 patients, 29.9%; p = 0.015). Preparatory BAV was always performed when the other THVs were used.

Mortality at 30 days and 1 year was not significantly different between the five THV groups (ES3, MER or MEP, SAN, DF, Portico; 4.0 vs. 6.8 vs. 7.1 vs. 5.3% vs. 0% and 15.4 vs. 9.1 vs. 16.5 vs. 5.3% vs. 0%, respectively, log-rank p = 0.665).

Discussion

The present study demonstrates that TF-TAVR can be safely performed on the very old patient population with similar outcomes to younger patients. Procedural simplification might lead to lower complication rates after TAVR especially in the very fragile population with increased age. In this analysis, the prevalence of stroke and minor or major vascular complications that have been previously associated with increased age was not significantly increased in the patients over 85 years undergoing TF-TAVR [5, 7, 14, 15]. In addition, age did not significantly impact the outcomes of patients undergoing TF-TAVR.

Impact of age on outcome

Randomized control studies have shown that age was not an independent determinant of 1-year mortality [4]. Nevertheless, comorbidities may influence the outcome of younger patients, which can explain the similar survival rates between different age groups [4]. On the other hand, there are data showing an association between increasing age and in-hospital mortality after TAVR [4, 6, 14, 15]. In a similar analysis, there was a trend toward higher 30-day and 6-month mortality in patients older than 90 years old; however, the difference was not significant [16]. In the present study, contrary to what was expected based on the significantly higher operative risk and fragility of very old patients, patients aged >85 years had a better outcome than did patients aged 76–80 and 81–85 years, most likely as a result of more serious comorbid conditions limiting life expectancy.

Incidence of age-associated complications and impact of increased fragility

The geriatric population has grown, leading to an increased number of patients undergoing TAVR. Taking this epidemiological fact into consideration, improve-
ments in transcatheter technology and increased operator experience leading to further simplification of the procedure are key to achieving the best result in such a fragile population [6, 7].

According to recent data, the incidence of peri-procedural complications defined by the Valve Academic Research Consortium may be similar between the different age groups [4]. Nevertheless, stroke and vascular complications have been observed more frequently in TAVR patients of increased age [5, 7, 14, 15]. The degree of vascular calcification and frailty may play an important role in these observations; however, this remains hypothetical and needs further investigation [6].

In this study, the incidence of stroke and vascular complications was not higher in the very old patient group undergoing TF-TAVR. This analysis shows that TF-TAVR can be performed with similar good procedural results in the continuously increasing very old patient population.

Interestingly, very old patients of group 4 had a significantly lower weight and height. Low BMI has been associated with significantly worse outcome and is considered an independent predictor of mortality [4]. In addition, as expected due to the increased age, the logistic EuroSCORE was significantly higher in the group of very old patients. Therefore, based on current data, the very old population of group 4 had an unfavorable starting position compared with the younger patients. This analysis showed that despite significantly increased fragility proved by quantitative parameters of pre-interventional risk stratification (height, weight, logistic EuroSCORE), TF-TAVR can be safely performed with very good outcomes even in very old high-risk patients. Moreover, this study demonstrated non-significant trends towards lower mortality rates in group 4.

A current analysis has shown that modern direct TAVR, performed without the use of preparatory BAV, leads to lower complication rates probably due to the simplification of the procedure [7]. Over 5000 patients were analyzed, showing significant advantages for the patients undergoing direct TAVR (quicker procedures, lower amounts of contrast and radiation, lower tamponade rates; [7]). In this study, direct implantation without preparatory BAV was more frequently performed on patients aged >85 years. In our hands, direct TF-TAVR may provide a simple method to decrease such “age-associated” complications not only by reducing unnecessary exchange maneuvers in the aortic arch and the left ventricle but also at the same time by avoiding the additional rapid pacing needed for the BAV. The positive impact of direct TF-TAVR in terms of procedure simplification could partly explain the similarly low rates of “age-associated” complications in the very old patient group compared with the younger patients, although this remains speculative and requires further investigation.

Balloon aortic valvuloplasty can improve annular sizing, facilitate the delivery system passing through the stenotic native valve, and is supposed to optimize valve expansion [7, 17]. Nevertheless, BAV has been related to hemodynamic instability, acute aortic regurgitation, renal failure, increased incidence of stroke, and pacemaker implantation [7, 18–20].

**Conclusion**

Outcome after transfemoral–transcatheter aortic valve replacement is comparable among different age cohorts, even in very old patients. Direct implantation may be key for further reduction of peri-interventional complications especially in patients of advanced age. Age per se is not a strong parameter for pre-interventional risk stratification.

**Corresponding address**

Polykarpos C. Patsalis, MD
Heart Center Bergmannsheil, Department of Cardiology and Angiology, University Hospital Bergmannsheil, Ruhr University Bochum
Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
polykarpos.patsalis@ruhr-uni-bochum.de

**Author Contribution.** Kaffer Kara, Axel Kloppe and Polykarpos C. Patsalis, conceived the study, acquired, analyzed, and interpreted the data and drafted the manuscript. Aydan Ewers, Leif Ilja Bösche, Assem Awweimer, Habil Erdogan, Dominik Schöne, Fabian Schiedat, Nikolaos Patsalis, Peter Lukas Haldenwang acquired and analyzed the data and revised the manuscript critically for important intellectual content. Justus Thomas Strauch and Andreas Mügge made substantial intellectual contributions to the conception and design of the study and revised the manuscript critically for important intellectual content.

**Table 2** Assessment of paravalvular leakage age severity

| PVL | ≤85 years (n = 279) | >85 years (n = 111) | p     |
|-----|-------------------|-------------------|-------|
| A   |                   |                   |       |
| Absent (0/4) | 180 (64.5%) | 78 (70.3%) | –     |
| Trace or mild (1/4) | 70 (25.1%) | 27 (24.3%) | –     |
| Moderate (2/4) | 29 (10.4%) | 6 (5.4%) | 0.27  |
| Moderate-to-severe (3/4) | 0 (0%) | 0 (0%) | –     |
| Severe (4/4) | 0 (0%) | 0 (0%) | –     |
| B   |                   |                   |       |
| ΔPDAP–LVEDP <18 mm Hg | 37 (13.7%) | 10 (9.1%) | 0.30  |

The distribution of postprocedural paravalvular leakage (PVL) after transfemoral transcatheter aortic valve replacement (TF-TAVR; A) and invasive hemodynamics (B). Values are n (%).

**Limitations**

Our data are derived from a retrospective analysis of consecutive patients and not from a prospective, randomized trial. We therefore cannot exclude that part of the observed, not necessarily expected, benefit in group 4 is due to a learning curve and not specifically to the technique of direct implantation. In this study, direct TF-TAVR was intermittently performed on very old patients according to a procedure simplification. Further investigation is necessary to evaluate whether the positive impact of direct TF-TAVR in patients with advanced age remains if direct implantation is routinely and evenly used in all age groups. However, direct-TAVR is not always applicable and preparatory BAV can still be a necessity for many patients [17]. Therefore, the conclusion on the impact of direct TAVR remains hypothetical.
Compliance with ethical guidelines

Conflict of interest. K. Kara, A. Kloppe, A. Evvers, L. Bosche, A. Aweimer, H. Erdogan, D. Schone, F. Schiedat, N. Patsalis, P.L. Haldenwang, J.T. Strauch and A. Mugge declare that they have no competing interests. P.C. Patsalis is proctor for Edwards Lifesciences.

This retrospective study received ethical approval from the “Ethical Commission of the Ruhr University, Bochum”.

Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kodali SK, Williams MR, Smith CR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366(18):1686–1695
2. Webb JG, Pasupati S, Humphries K et al (2007) Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 116:753–763
3. Makkar RR, Fontana GP, Jilaihawi H et al (2012) Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 366:1696–1704
4. van der Kley F, an Rosendael PJ, Katsanos S et al (2016) Impact of age on transcatheter aortic valve implantation outcomes: a comparison of patients aged ≤80 years versus patients aged >80 years. J Geriatr Cardiol 13:31–36
5. Jung B, Vahanian A (2014) Epidemiology of acquired valvular heart disease. Can J Cardiol 30:9(9):962–970. https://doi.org/10.1016/j.cjca.2014.03.022
6. Alsara O, Alsarah A, Laird-Fick H (2014) Advanced age and the clinical outcomes of transcatheter aortic valve implantation. J Geriatr Cardiol 11:163–170
7. Deharo P, Juassaud N, Grisoli D et al (2018) Impact of direct TAVR without balloon aortic valvuloplasty on procedural and clinical outcomes. JACC Cardiovasc Interv 11(19):1956–1965 (Oct)
8. Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308
9. Vahanian A, Alfieri O, Al-Attar N et al (2008) Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 29:1463–1470
10. Kappetein AP, Head SJ, Genereux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation. The valve academic research consortium-2 consensus document. J Am Coll Cardiol 60:1438–1454
11. ESC Scientific Document Group, Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791
12. Patsalis PC, Al-Rashid F, Neumann T et al (2013) Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved valve sizing. JACC Cardiovasc Interv 6(9):965–971
13. Sellers RO, Levy MJ, Amplatzer K, Lillehei CW (1964) Left retrograde cardioangiography in acquired cardiac disease: technic, indications and interpretations in 700 cases. Am J Cardiol 14:437–447
14. Havakuk O, Finkelstein A, Steinviel A et al (2014) Am J Cardiol 113:138–141
15. Yamamoto M, Meguro K, Mouillet G et al (2012) Comparison of effectiveness and safety of transcatheter aortic valve implantation in patients aged 90 years versus (90 years. Am J Cardiol 110:1156–1163
16. Di Mario C, Eltchaninoff H, Moat N et al (2013) The 2011–2012 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: inhospital results in 4,571 patients. EuroIntervention 8:1362–1371
17. Patsalis PC, Al-Rashid F, Neumann T et al (2013) Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved valve sizing. JACC Cardiovasc Interv 6(9):965–971
18. Ben-Dor I, Pichard AD, Satler LF et al (2010) Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients. J Am Coll Cardiol Intv 3:1150–1156
19. Lange P, Greif M, Voge A et al (2014) Reduction of pacemaker implantation rates after CoreValve® implantation by moderate predilatation. EuroIntervention 9:1151–1157
20. Eltchaninoff H, Durand E, Borz B et al (2014) Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: acute and long-term outcomes. Am Heart J 167:235–240